Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/49446| Title: | Impact of rivaroxaban in cardiovascular disease |
| Authors: | Cardona, Mark Wirth, Francesca Serracino-Inglott, Anthony Xuereb, Robert G. Azzopardi, Lilian M. |
| Keywords: | Rivaroxaban Anticoagulants (Medicine) -- Case studies Warfarin Cardiovascular Disease -- Chemotherapy |
| Issue Date: | 2017-10 |
| Publisher: | University of Malta. Department of Pharmacy |
| Citation: | Cardona, M., Wirth, F., Serracino-Inglott, A., Xuereb, R. G., & Azzopardi, L. M. (2017, October). Impact of rivaroxaban in cardiovascular disease. Poster session presented at the 46th European Symposium on Clinical Pharmacy, Heidelberg, Germany. |
| Abstract: | A poster presentation regarding the Impact of rivaroxaban in cardiovascular disease. Background: Compared to warfarin, the novel oral anticoagulant (NOAC) rivaroxaban has the advantages of a fixed dosing regimen with no need for INR monitoring and fewer potential drug-drug interactions (DDIs), which have been reported to improve adherence to treatment. Objectives: • To determine INR control for patients on warfarin • To compare warfarin to rivaroxaban with respect to treatment adherence, incidence and severity of bleeding and potential DDIs. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/49446 |
| Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Impact_of_rivaroxaban_in_cardiovascular_disease_2017.pdf | 442.84 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.